Literature DB >> 25561350

Dosing algorithm revisit for busulfan following IV infusion.

Yanlin Wang1, Kazunobu Kato, Christopher Le Gallo, Elizabeth Armstrong, Edwin Rock, Xiaofeng Wang.   

Abstract

PURPOSE: Busulfan (Bu) exposure is critical for efficacy and safety. Body weight (BW), or adjusted ideal body weight (AIBW)-based dosing (WBD) algorithm, has been used in hematopoietic stem cell transplantation (HSCT). A recently completed phase 2 study revealed that 33.6 % of the subjects were under-, or over-exposed, with this WBD algorithm. This paper was to investigate Bu dosing algorithm in an attempt to improve the suboptimal Bu exposure.
METHODS: Population PK modeling was conducted using the data from 207 patients. Dosing algorithm was developed based on derived covariate model of CL. Model-based simulation was conducted to assist test PK study design. A simplified CL estimation method was proposed based on the PK structure model for Bu.
RESULTS: A one-compartment structure model adequately described the PK profile of Bu following an IV infusion. BSA best described the inter-individual variability of CL. The proposed dosing algorithm was dose (mg) = (31.7 × BSA - 11.6) × target AUC [µM min]/1,000. With this dosing algorithm, 14.3 % patients could be under- or over-exposed. A test PK study with reduced study duration and three PK samples can provide as nearly as good an estimate of CL compared to 12 PK samples on two different occasions.
CONCLUSION: The proposed dosing algorithm can significantly improve the sub-exposure of Bu. A shortened test PK study duration with reduced PK samples can provide as near as good estimate for Bu CL. A simplified CL estimation method is valid.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25561350     DOI: 10.1007/s00280-014-2660-0

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

1.  The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study.

Authors:  Xiaohuan Du; Chenrong Huang; Ling Xue; Zheng Jiao; Min Zhu; Jie Li; Jun Lu; Peifang Xiao; Xuemei Zhou; Chenmei Mao; Zengyan Zhu; Ji Dong; Xiaoxue Liu; Zhiyao Chen; Shichao Zhang; Yiduo Ding; Shaoyan Hu; Liyan Miao
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

2.  Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.

Authors:  Christopher R Flowers; Luciano J Costa; Marcelo C Pasquini; Jennifer Le-Rademacher; Michael Lill; Tsiporah B Shore; William Vaughan; Michael Craig; Cesar O Freytes; Thomas C Shea; Mitchell E Horwitz; Joseph W Fay; Shin Mineishi; Damiano Rondelli; James Mason; Ira Braunschweig; Weiyun Ai; Rosa F Yeh; Tulio E Rodriguez; Ian Flinn; Terrance Comeau; Andrew M Yeager; Michael A Pulsipher; Isabelle Bence-Bruckler; Pierre Laneuville; Philip Bierman; Andy I Chen; Kazunobu Kato; Yanlin Wang; Cong Xu; Angela J Smith; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2016-03-31       Impact factor: 5.742

3.  Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation.

Authors:  Claire Seydoux; Raphael Battegay; Joerg Halter; Dominik Heim; Katharina M Rentsch; Jakob R Passweg; Michael Medinger
Journal:  Bone Marrow Transplant       Date:  2022-03-31       Impact factor: 5.174

4.  External Evaluation of Population Pharmacokinetic Models of Busulfan in Chinese Adult Hematopoietic Stem Cell Transplantation Recipients.

Authors:  Huiping Huang; Qingxia Liu; Xiaohan Zhang; Helin Xie; Maobai Liu; Nupur Chaphekar; Xuemei Wu
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.